In an initial trial, 37 children who received the gene therapy were all still alive at age 6, most could talk, walk, and perform well on IQ tests.
The price set by Lenmeldy for the US market exceeds experts' calculations for a fair price, potentially causing significant challenges for healthcare systems.
[
add
]
[
|
|
...
]